URUS’s $170 Million Acquisition of Trans Ova Genetics

Davis Polk advised Precigen on the deal.Precigen, Inc. executed the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. (“Trans Ova”), an industry-leading animal reproductive…

This content is for members only.
Login to Read More Join Now
Laura Testa

Author: Laura Testa

This content is for members only.
Login to Read More Join Now